Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria

@article{Borba2006MycophenolateMI,
  title={Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria},
  author={Eduardo Ferreira Borba and Lissiane Karine Noronha Guedes and R. Christmann and Camille Pinto Figueiredo and C{\'e}lio Roberto Gonçalves and Elo{\'i}sa Silva Dutra de Oliveira Bonf{\'a}},
  journal={Rheumatology International},
  year={2006},
  volume={26},
  pages={1078-1083}
}
Mycophenolate mofetil (MMF) significantly reduces proteinuria in experimental model of human membranous nephropathy (Heymann nephritis). Twenty consecutive SLE patients with persistent isolated severe proteinuria and/or proteinuric flare were studied for 18 months of MMF therapy. All of them presented stable renal function and 12 had biopsy proven membranous glomerulonephritis (WHO class V). The starting daily dose for MMF was 1.5 g to a maximum of 3 g. Patients were divided into: partial… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

Systematic review and meta-analysis of immunosuppressant therapy clinical trials in membranous lupus nephritis.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research • 2011

Use of mycophenolic acid in non-transplant renal diseases.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association • 2007

References

Publications referenced by this paper.
Showing 1-10 of 48 references

Sequential therapies for proliferative lupus nephritis.

The New England journal of medicine • 2004
View 1 Excerpt

A multicenter study of mycophenolate mofetil ( MMF ) vs . intravenous cyclophosphamide ( FYC ) as induction therapy for severe lupus nephritis ( LN ) Preliminary results

EM Ginzler, C Aranow, +7 authors M Weisman
Arthritis Rheum • 2003

A multicenter study of mycophenolate mofetil (MMF) vs. intravenous cyclophosphamide (FYC) as induction therapy for severe lupus nephritis

EM Ginzler, C Aranow, +7 authors M Weisman
(LN) Preliminary results. Arthritis Rheum • 2003
View 1 Excerpt

Similar Papers

Loading similar papers…